The fecal microbiota as a biomarker for disease activity in Crohn’s disease

Monitoring mucosal inflammation is crucial to prevent complications and disease progression in Crohn’s disease (CD). Endoscopy is the current standard, but is invasive. Clinical activity scores and non-invasive biochemical markers do not correlate well with mucosal inflammation. Microbial perturbations have been associated with disease activity in CD. Therefore, we aimed to investigate its potential use to differentiate CD patients in remission from those with an exacerbation. From 71 CD patients repeated fecal samples were collected, resulting in 97 active disease and 97 remission samples based on a combination of biochemical and clinical parameters. The microbiota composition was assessed by pyrosequencing of the 16S rRNA V1-V3 region. Random Forest analysis was used to find the most discriminatory panel of operational taxonomic units (OTUs) between active and remission samples. An independent internal validation set was used to validate the model. A combination of 50 OTUs was able to correctly predict 73% of remission and 79% of active samples with an AUC of 0.82 (sensitivity: 0.79, specificity: 0.73). This study demonstrates that fecal microbial profiles can be used to differentiate between active and remission CD and underline the potential of the fecal microbiota as a non-invasive tool to monitor disease activity in CD.

[1]  C. Manichanh,et al.  Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.

[2]  J. Doré,et al.  Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon , 2003, Gut.

[3]  A. Leslie Robb,et al.  Alternative Transformations to Handle Extreme Values of the Dependent Variable , 1988 .

[4]  U. Gophna,et al.  Differences between Tissue-Associated Intestinal Microfloras of Patients with Crohn's Disease and Ulcerative Colitis , 2006, Journal of Clinical Microbiology.

[5]  Takanori Kanai,et al.  The gut microbiota and inflammatory bowel disease , 2014, Seminars in Immunopathology.

[6]  T. Matsui,et al.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease , 2012, Journal of Gastroenterology.

[7]  Age K. Smilde,et al.  Multivariate paired data analysis: multilevel PLSDA versus OPLSDA , 2009, Metabolomics.

[8]  Eric J. Alm,et al.  Non-Invasive Mapping of the Gastrointestinal Microbiota Identifies Children with Inflammatory Bowel Disease , 2012, PloS one.

[9]  B. Wiedenmann,et al.  Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn's disease and the effect of therapy , 2012, Inflammatory bowel diseases.

[10]  M. Surette,et al.  Mesalazine (5‐aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea‐predominant irritable bowel syndrome , 2011, Alimentary pharmacology & therapeutics.

[11]  A. Verma,et al.  Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India , 2010, Journal of Clinical Microbiology.

[12]  F. Shanahan,et al.  Culture-Independent Analyses of Temporal Variation of the Dominant Fecal Microbiota and Targeted Bacterial Subgroups in Crohn's Disease , 2006, Journal of Clinical Microbiology.

[13]  J. Doré,et al.  Low counts of Faecalibacterium prausnitzii in colitis microbiota , 2009, Inflammatory bowel diseases.

[14]  J. Doré,et al.  Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.

[15]  Chris McSweeney,et al.  Association between specific mucosa‐associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: A pilot study , 2015, Journal of gastroenterology and hepatology.

[16]  Janet K. Jansson,et al.  Twin studies reveal specific imbalances in the mucosa‐associated microbiota of patients with ileal Crohn's disease , 2009, Inflammatory bowel diseases.

[17]  P. Lakatos,et al.  The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.

[18]  Jan Verhaegen,et al.  A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis , 2013, Gut.

[19]  D. Laukens,et al.  Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. , 2012, FEMS microbiology ecology.

[20]  J. Silva,et al.  Bacteroides fragilis enterotoxin gene sequences in patients with inflammatory bowel disease. , 2000, Emerging infectious diseases.

[21]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[22]  Julian Parkhill,et al.  High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease , 2011, BMC Microbiology.

[23]  Richard Hansen,et al.  Microbiota of De-Novo Pediatric IBD: Increased Faecalibacterium Prausnitzii and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis , 2012, The American Journal of Gastroenterology.

[24]  Berthold Lausen,et al.  Classification of repeated measurements data using tree-based ensemble methods , 2011, Comput. Stat..

[25]  S. Vermeire,et al.  Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[26]  Harjinder Singh,et al.  A first study on the incidence and prevalence of IBD in Malaysia--results from the Kinta Valley IBD Epidemiology Study. , 2015, Journal of Crohn's & colitis.

[27]  W. Sandborn,et al.  Crohn's disease , 2012, The Lancet.

[28]  P. Rutgeerts,et al.  Laboratory markers in IBD: useful, magic, or unnecessary toys? , 2006, Gut.

[29]  L. Buydens,et al.  Regularized MANOVA (rMANOVA) in untargeted metabolomics. , 2015, Analytica chimica acta.

[30]  Y. Benno,et al.  Faecal microbiota profile of Crohn’s disease determined by terminal restriction fragment length polymorphism analysis , 2009, Alimentary pharmacology & therapeutics.

[31]  H. Ogata,et al.  Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. , 2008, International journal of medical microbiology : IJMM.

[32]  C. Manichanh,et al.  Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach , 2005, Gut.

[33]  K. Palmer,et al.  Complications of gastrointestinal endoscopy , 2007, Gut.

[34]  M. Zeegers,et al.  Cohort Profile Cohort Profile : The Inflammatory Bowel Disease South Limburg Cohort ( IBDSL ) , 2015 .

[35]  Alexandra Bazeos,et al.  Are Helicobacter Species and Enterotoxigenic Bacteroides fragilis Involved in Inflammatory Bowel Disease? , 2004, Digestive Diseases and Sciences.

[36]  S. Erlandsen,et al.  Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. , 1996, Gastroenterology.

[37]  G. Rogler.  Gastrointestinal and liver adverse effects of drugs used for treating IBD. , 2010, Best practice & research. Clinical gastroenterology.

[38]  D. Williamson,et al.  The box plot: a simple visual method to interpret data. , 1989, Annals of internal medicine.

[39]  J. Garcia-Gil,et al.  Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. , 2015, Journal of Crohn's & colitis.

[40]  Zlatan Mujagic,et al.  Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach , 2015, Inflammatory bowel diseases.

[41]  E. Zoetendal,et al.  Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation , 2015, The American Journal of Gastroenterology.

[42]  S. Hagel,et al.  Adverse effects of biologics used for treating IBD. , 2010, Best practice & research. Clinical gastroenterology.

[43]  R. Knight,et al.  Supervised classification of human microbiota. , 2011, FEMS microbiology reviews.

[44]  Laurent Beaugerie,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.

[45]  O. Inatomi,et al.  Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis , 2011, Journal of Gastroenterology.

[46]  Se Jin Song,et al.  The treatment-naive microbiome in new-onset Crohn's disease. , 2014, Cell host & microbe.

[47]  J. Paul,et al.  Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. , 2013, World journal of gastroenterology.

[48]  P. Savelkoul,et al.  Fecal Microbial Composition of Ulcerative Colitis and Crohn’s Disease Patients in Remission and Subsequent Exacerbation , 2014, PloS one.

[49]  Bing Xia,et al.  Increased Proportions of Bifidobacterium and the Lactobacillus Group and Loss of Butyrate-Producing Bacteria in Inflammatory Bowel Disease , 2013, Journal of Clinical Microbiology.

[50]  M. Inouye,et al.  Recent Advances in Characterizing the Gastrointestinal Microbiome in Crohn's Disease: A Systematic Review , 2015, Inflammatory bowel diseases.

[51]  Jingjing Ma,et al.  Use of antibiotics in patients with Crohn's disease: A systematic review and meta‐analysis , 2015, Journal of digestive diseases.

[52]  M. Färkkilä,et al.  Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2012, Scandinavian journal of gastroenterology.

[53]  M. Kamm,et al.  Impact of Drug Therapy and Surgery on Quality of Life in Crohn's Disease: A Systematic Review , 2015, Inflammatory bowel diseases.

[54]  R. Gearry,et al.  Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission , 2015, Inflammatory bowel diseases.

[55]  Mario Vaneechoutte,et al.  Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora , 2008, Inflammatory bowel diseases.

[56]  Jonas S. Almeida,et al.  An Introspective Comparison of Random Forest-Based Classifiers for the Analysis of Cluster-Correlated Data by Way of RF++ , 2009, PloS one.

[57]  Francisco Guarner,et al.  The gut microbiota in IBD , 2012, Nature Reviews Gastroenterology &Hepatology.